Browsing Tag
biotechnology
67 posts
Rigel Pharmaceuticals’ R289 delivers promising phase 1b results in transfusion-dependent MDS
Find out how Rigel Pharmaceuticals, Inc. is advancing R289 for lower-risk myelodysplastic syndrome with promising new phase 1b data—read the latest insights now!
Kala Bio launches $10m registered direct financing amid balance sheet reset and dilution concerns
Find out how Kala Bio’s $10 million at-the-market stock offering under Nasdaq rules is reshaping its balance sheet, dilution risk, and survival strategy.
SciSparc targets quantum-powered bio data analysis with NeuroThera majority acquisition move
Find out how SciSparc is moving into quantum-powered bio data analysis through NeuroThera’s majority acquisition plan and what it could mean for investors.
Vanda Pharmaceuticals (NASDAQ: VNDA) gains after FDA sets new December 5 date for tradipitant re-review
Vanda Pharmaceuticals moves closer to FDA approval for tradipitant in motion sickness while targeting the GLP-1 side effect market. Find out what’s next.
Johnson & Johnson grabs RIPTAC cancer tech in $3bn Halda Therapeutics deal
Johnson & Johnson acquires Halda Therapeutics for $3.05B, expanding its oncology portfolio with precision prostate cancer treatments. Find out what’s next.
Phase 2 trial of Nasus Pharma’s NS002 needle-free epinephrine starts with initial dosing milestone
Find out how Nasus Pharma is advancing NS002, its needle-free intranasal epinephrine candidate, into Phase 2 trials and what it means for emergency allergy care.
Investors watch Nuvalent ahead of pivotal neladalkib ALKOVE-1 topline data in resistant ALK-positive NSCLC
Nuvalent will unveil pivotal ALKOVE-1 data for neladalkib in TKI-pretreated ALK-positive NSCLC on November 17. Explore why investors believe this readout could redefine targeted lung cancer care.
Salarius Pharmaceuticals raises $7m in underwritten offering to fund merger and R&D pipeline
Find out how Salarius Pharmaceuticals is raising $7 million through a structured equity offering as it funds a merger and next-generation biotech pipeline.
Immuron secures FDA greenlight to begin human studies of IMM-529 against C. difficile infection
Immuron gains FDA IND approval for IMM-529, advancing its oral antibody therapy into human trials for C. difficile infection.
Ernexa’s ERNA-101 cell therapy takes major step toward clinical trials through Cellipont manufacturing deal
Discover how Ernexa Therapeutics and Cellipont Bioservices are teaming up to manufacture ERNA-101 for ovarian cancer, marking a milestone in allogeneic cell therapy.